

Amendments to the Specification

On page 3, please replace the second paragraph with the following amended paragraph:

For example, elevation of the cardiac function due to administration of ubiquinone has been reported [Kishi, T. et al., Clin. Investg., 71, S71-S75 (1993)]; ameliorating efficacy in cardiac diseases such as congestive heart failure, angina pectoris, myocardial infarction, etc. by ubiquinone [Singh, R.B. et al., Inter. J. Cardiology, 68, 23-29 (1999), Singh, R.B. et al., Cardiovasc. Drugs Ther., 12, 347-353 (1998)]; preventive and ameliorative efficacy in atherosclerosis, hypertension, diabetes, cancer, periodontal diseases, and allergies [Singh, RB. et al., Atherosclerosis, 148, 275-282 (1999)2000, Digiesi, V., et al., Curr. Therap. Res., 51, 668-672 (1992), Kishi, T., et al., Journal of Dental Health, 43, 667-672 (1993), Shimura Y., et al., Rinsho-to-Kenkyu, 58, 1349-1352 (1981)]; reproductive potential-improving effect, inhibition of oxidation of LDL cholesterol, dialysis frequency-reducing effect in renal dialysis patients, nonspecific immunity-potentiating effect, and the like are known [Stocker et al., Mol. Aspects Med., 18, S85-S103 (1997), Lippa, S., Mol. Aspects Med., 15, S213-S219 (1994)]. Furthermore, ubiquinone is already in use clinically as a therapeutic drug for the palpitation, short breadth, and anasarca arising from congestive heart failure or mild heart diseases.